Swedish Orphan Biovitrum AB

About Us

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.

Contacts

Visiting address

Norra Stationsgatan 93A, Sweden

+46 8 697 20 00
info@sobi.com

Gerard Tobin

Head of Investor Relations

gerard.tobin@sobi.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

First patients enrolled in 24 month real-world study evaluating effectiveness of Elocta®

Thu, Jan 19, 2017 09:00 CET

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the first patients have been enrolled in the A-SURE study (NCT02976753). A-SURE is a 24-month real-world study evaluating the effectiveness of Elocta® compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A in Europe. The efficacy and safety of Elocta have been established in clinical trials and the A-SURE study will provide data from a real-world setting, which can be made available to physicians, payers and reimbursement authorities in evaluating the

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Contacts

First patients enrolled in 24 month real-world study evaluating effectiveness of Elocta®

Subscribe